JP2008529497A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008529497A5 JP2008529497A5 JP2007554287A JP2007554287A JP2008529497A5 JP 2008529497 A5 JP2008529497 A5 JP 2008529497A5 JP 2007554287 A JP2007554287 A JP 2007554287A JP 2007554287 A JP2007554287 A JP 2007554287A JP 2008529497 A5 JP2008529497 A5 JP 2008529497A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- isolated antibody
- epha2
- antigen
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims 34
- 102000051096 EphA2 Receptor Human genes 0.000 claims 26
- 108010055196 EphA2 Receptor Proteins 0.000 claims 26
- 239000012634 fragment Substances 0.000 claims 26
- 239000000427 antigen Substances 0.000 claims 25
- 108091007433 antigens Proteins 0.000 claims 25
- 102000036639 antigens Human genes 0.000 claims 25
- 206010028980 Neoplasm Diseases 0.000 claims 9
- 201000011510 cancer Diseases 0.000 claims 9
- 101150042817 NFS1 gene Proteins 0.000 claims 8
- 101100126298 Rickettsia conorii (strain ATCC VR-613 / Malish 7) iscS gene Proteins 0.000 claims 8
- 101150114492 SPL1 gene Proteins 0.000 claims 8
- 150000007523 nucleic acids Chemical group 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 7
- 108020004707 nucleic acids Proteins 0.000 claims 7
- 102000039446 nucleic acids Human genes 0.000 claims 7
- 229940124597 therapeutic agent Drugs 0.000 claims 7
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 238000000338 in vitro Methods 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 claims 2
- 210000004881 tumor cell Anatomy 0.000 claims 2
- 230000004614 tumor growth Effects 0.000 claims 2
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 210000004408 hybridoma Anatomy 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65004705P | 2005-02-04 | 2005-02-04 | |
| US60/650,047 | 2005-02-04 | ||
| PCT/US2006/004057 WO2006084226A2 (en) | 2005-02-04 | 2006-02-06 | Antibodies that bind to epha2 and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008529497A JP2008529497A (ja) | 2008-08-07 |
| JP2008529497A5 true JP2008529497A5 (enExample) | 2009-04-02 |
| JP5342145B2 JP5342145B2 (ja) | 2013-11-13 |
Family
ID=36778009
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007554287A Expired - Fee Related JP5342145B2 (ja) | 2005-02-04 | 2006-02-06 | ＥｐｈＡ２に結合する抗体およびその使用方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US7569672B2 (enExample) |
| EP (1) | EP1846450B1 (enExample) |
| JP (1) | JP5342145B2 (enExample) |
| KR (1) | KR101363252B1 (enExample) |
| CN (2) | CN104059150B (enExample) |
| AT (1) | ATE551367T1 (enExample) |
| AU (1) | AU2006210460B2 (enExample) |
| BR (1) | BRPI0607450A2 (enExample) |
| CA (1) | CA2597198C (enExample) |
| CR (1) | CR9332A (enExample) |
| IL (1) | IL184803A (enExample) |
| MX (1) | MX2007009403A (enExample) |
| NO (1) | NO20074474L (enExample) |
| RU (1) | RU2007133108A (enExample) |
| WO (1) | WO2006084226A2 (enExample) |
| ZA (1) | ZA200707275B (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7192698B1 (en) * | 1999-08-17 | 2007-03-20 | Purdue Research Foundation | EphA2 as a diagnostic target for metastatic cancer |
| US6927203B1 (en) * | 1999-08-17 | 2005-08-09 | Purdue Research Foundation | Treatment of metastatic disease |
| AU2006210460B2 (en) * | 2005-02-04 | 2012-04-05 | Macrogenics West, Inc. | Antibodies that bind to EphA2 and methods of use thereof |
| AU2006287416A1 (en) * | 2005-09-07 | 2007-03-15 | Medimmune, Llc | Toxin conjugated Eph receptor antibodies |
| NZ574215A (en) | 2006-07-18 | 2012-07-27 | Sanofi Aventis | Antagonist antibody against epha2 for the treatment of cancer |
| US8309354B2 (en) | 2007-01-22 | 2012-11-13 | Macrogenics West, Inc. | Human cancer stem cells |
| CN101918844A (zh) * | 2007-06-18 | 2010-12-15 | 米迪缪尼有限公司 | 表达epha2和erbb2的细胞的协同治疗 |
| WO2009028639A1 (ja) | 2007-08-30 | 2009-03-05 | Daiichi Sankyo Company, Limited | 抗ｅｐｈａ２抗体 |
| EP2223112A2 (en) * | 2007-12-21 | 2010-09-01 | Siemens Healthcare Diagnostics Inc. | Circulating epha2 receptor |
| US8669349B2 (en) | 2008-04-02 | 2014-03-11 | Macrogenics, Inc. | BCR-complex-specific antibodies and methods of using same |
| JP5117917B2 (ja) | 2008-04-21 | 2013-01-16 | デクセリアルズ株式会社 | 保護素子及びその製造方法 |
| EP2679238A1 (en) | 2008-10-02 | 2014-01-01 | Celtaxsys, INC. | Methods of modulating the negative chemotaxis of immune cells |
| SG172254A1 (en) | 2008-12-19 | 2011-07-28 | Macrogenics Inc | Covalent diabodies and uses thereof |
| UY32914A (es) | 2009-10-02 | 2011-04-29 | Sanofi Aventis | Anticuerpos que se usan específicamente al receptor epha2 |
| DK2498796T3 (en) | 2009-11-09 | 2018-03-05 | Aal Scient Inc | HEART DISEASE TREATMENT |
| US20120288481A1 (en) * | 2009-11-09 | 2012-11-15 | The Brigham And Women's Hospital, Inc. | Treatment of heart disease |
| PH12012501751A1 (en) | 2010-03-04 | 2012-11-12 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| DK2542256T3 (da) | 2010-03-04 | 2019-08-26 | Macrogenics Inc | Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf |
| KR20130048242A (ko) * | 2010-07-22 | 2013-05-09 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 항-종양 항원 항체 및 이용 방법 |
| CA2807127C (en) | 2010-08-02 | 2019-02-12 | Leslie S. Johnson | Covalent diabodies and uses thereof |
| WO2012162068A2 (en) | 2011-05-21 | 2012-11-29 | Macrogenics, Inc. | Deimmunized serum-binding domains and their use for extending serum half-life |
| MX2014002289A (es) | 2011-08-26 | 2015-03-20 | Merrimack Pharmaceuticals Inc | Anticuerpos fc especificos en tandem. |
| AU2012318590B2 (en) * | 2011-10-04 | 2017-05-18 | Expression Pathology, Inc. | SRM/MRM assay for the ephrin type-A receptor 2 protein |
| JP5875054B2 (ja) * | 2013-02-13 | 2016-03-02 | 国立大学法人 東京大学 | がんの検査方法及び検査用キット |
| US9487587B2 (en) | 2013-03-05 | 2016-11-08 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof |
| MX2015011712A (es) | 2013-03-06 | 2016-04-04 | Merrimack Pharmaceuticals Inc | Anticerpos biespecificos fc en fila anti-c-met. |
| TWI742423B (zh) | 2014-05-29 | 2021-10-11 | 美商宏觀基因股份有限公司 | 特異性結合多種癌症抗原的三特異性結合分子和其使用方法 |
| KR101636882B1 (ko) * | 2015-06-25 | 2016-07-06 | 전남대학교 산학협력단 | 인간 피브로넥틴 도메인 Ⅲ 기본 골격의 신규 인간 ＥｐｈＡ2 특이적 결합 단백질 및 그의 용도 |
| HUE055207T2 (hu) | 2015-07-30 | 2021-11-29 | Macrogenics Inc | PD-1 és LAG-3 kötõ molekulák és eljárások azok alkalmazására |
| EA201891178A1 (ru) | 2015-12-14 | 2019-01-31 | Макродженикс, Инк. | Биспецифичные молекулы, обладающие иммунореактивностью в отношении pd-1 и ctla-4, и способы их применения |
| US11534466B2 (en) | 2016-03-09 | 2022-12-27 | Aal Scientifics, Inc. | Pancreatic stem cells and uses thereof |
| TWI781098B (zh) | 2016-04-15 | 2022-10-21 | 美商宏觀基因股份有限公司 | 新穎的ｂ７-ｈ３-結合分子、其抗體藥物綴合物及其使用方法 |
| JPWO2018135653A1 (ja) * | 2017-01-23 | 2020-01-09 | 学校法人 東洋大学 | 抗ｅｐｈａ２抗体及びこれを用いたｅｐｈａ２の免疫学的検出 |
| SG11201907753TA (en) | 2017-02-24 | 2019-09-27 | Macrogenics Inc | Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof |
| WO2019118266A1 (en) | 2017-12-12 | 2019-06-20 | Macrogenics Inc. | Bispecific cd 16-binding molecules and their use in the treatment of disease |
| WO2019160904A1 (en) | 2018-02-15 | 2019-08-22 | Macrogenics, Inc. | Variant cd3-binding domains and their use in combination therapies for the treatment of disease |
| JP7326764B2 (ja) * | 2018-03-09 | 2023-08-16 | 東ソー株式会社 | 腫瘍マーカーならびに腫瘍細胞を夾雑細胞と区別して回収および検出する方法 |
| CA3170330A1 (en) | 2020-02-21 | 2021-08-26 | Macrogenics, Inc. | Cd137 binding molecules and uses thereof |
| IL298868A (en) * | 2020-06-12 | 2023-02-01 | Bicycletx Ltd | Treatment of diseases characterized by overexpression of hepatocyte receptor A2 that produces erythropoietin (EPHA2) |
| EP4349857A4 (en) | 2021-05-25 | 2025-06-11 | Vaxcell-Bio | Monobody-based chimeric antigen receptor and immune cell including same |
| KR20230140746A (ko) * | 2022-03-30 | 2023-10-10 | 연세대학교 산학협력단 | 암전이의 검출용 신규 바이오마커 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6054561A (en) | 1984-02-08 | 2000-04-25 | Chiron Corporation | Antigen-binding sites of antibody molecules specific for cancer antigens |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US5552391A (en) | 1990-01-16 | 1996-09-03 | La Jolla Pharmaceutical Company | Chemically-defined non-polymeric valency platform molecules and conjugates thereof |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| GB9115364D0 (en) | 1991-07-16 | 1991-08-28 | Wellcome Found | Antibody |
| CA2078539C (en) | 1991-09-18 | 2005-08-02 | Kenya Shitara | Process for producing humanized chimera antibody |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US5824303A (en) | 1992-11-13 | 1998-10-20 | Amgen Inc. | Eck receptor ligands |
| US6210671B1 (en) | 1992-12-01 | 2001-04-03 | Protein Design Labs, Inc. | Humanized antibodies reactive with L-selectin |
| US6180377B1 (en) | 1993-06-16 | 2001-01-30 | Celltech Therapeutics Limited | Humanized antibodies |
| US5532159A (en) | 1994-04-01 | 1996-07-02 | The Ohio State University | Monoclonal antibody to canine placental oncofetal protein for detecting cancer |
| US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
| CN1258539C (zh) | 1998-12-22 | 2006-06-07 | 雷文生物技术公司 | 用于产生特定类型细胞的代表性单克隆抗体的组合物及方法 |
| US6927203B1 (en) | 1999-08-17 | 2005-08-09 | Purdue Research Foundation | Treatment of metastatic disease |
| ES2357296T3 (es) | 1999-08-17 | 2011-04-25 | Purdue Research Foundation | Anticuerpos dirigidos contra epha2 como un diagnóstico de cáncer. |
| ATE324877T1 (de) | 1999-08-17 | 2006-06-15 | Purdue Research Foundation | Behandlung von metastatischer krankheit |
| US6849425B1 (en) | 1999-10-14 | 2005-02-01 | Ixsys, Inc. | Methods of optimizing antibody variable region binding affinity |
| US6406840B1 (en) | 1999-12-17 | 2002-06-18 | Biomosaic Systems, Inc. | Cell arrays and the uses thereof |
| US6541225B1 (en) | 2000-01-26 | 2003-04-01 | Raven Biotechnologies, Inc. | Methods and compositions for generating human monoclonal antibodies |
| US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
| FR2838742B1 (fr) | 2002-04-23 | 2004-07-09 | Inst Nat Sante Rech Med | Epitopes t de l'antigene epha2 |
| US20040028685A1 (en) * | 2002-05-10 | 2004-02-12 | Kinch Michael S. | EphA2 monoclonal antibodies and methods of use thereof |
| ES2377720T3 (es) | 2002-05-10 | 2012-03-30 | Purdue Research Foundation | Anticuerpos monoclonales agon�?sticos epha2 y métodos de uso de los mismos. |
| AU2006210460B2 (en) | 2005-02-04 | 2012-04-05 | Macrogenics West, Inc. | Antibodies that bind to EphA2 and methods of use thereof |
-
2006
- 2006-02-06 AU AU2006210460A patent/AU2006210460B2/en not_active Ceased
- 2006-02-06 WO PCT/US2006/004057 patent/WO2006084226A2/en not_active Ceased
- 2006-02-06 US US11/349,327 patent/US7569672B2/en not_active Expired - Fee Related
- 2006-02-06 EP EP06734397A patent/EP1846450B1/en not_active Expired - Lifetime
- 2006-02-06 KR KR1020077019628A patent/KR101363252B1/ko not_active Expired - Fee Related
- 2006-02-06 BR BRPI0607450-2A patent/BRPI0607450A2/pt not_active Application Discontinuation
- 2006-02-06 CN CN201410213409.1A patent/CN104059150B/zh not_active Expired - Fee Related
- 2006-02-06 MX MX2007009403A patent/MX2007009403A/es active IP Right Grant
- 2006-02-06 CN CN200680011089.5A patent/CN101155830B/zh not_active Expired - Fee Related
- 2006-02-06 RU RU2007133108/13A patent/RU2007133108A/ru not_active Application Discontinuation
- 2006-02-06 AT AT06734397T patent/ATE551367T1/de active
- 2006-02-06 CA CA2597198A patent/CA2597198C/en not_active Expired - Fee Related
- 2006-02-06 JP JP2007554287A patent/JP5342145B2/ja not_active Expired - Fee Related
- 2006-02-06 ZA ZA200707275A patent/ZA200707275B/xx unknown
-
2007
- 2007-07-24 IL IL184803A patent/IL184803A/en not_active IP Right Cessation
- 2007-08-22 CR CR9332A patent/CR9332A/es not_active Application Discontinuation
- 2007-09-03 NO NO20074474A patent/NO20074474L/no not_active Application Discontinuation
-
2009
- 2009-06-30 US US12/495,218 patent/US7776328B2/en not_active Expired - Fee Related
- 2009-11-30 US US12/627,335 patent/US8183357B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008529497A5 (enExample) | ||
| RU2007133108A (ru) | АНТИТЕЛА, СВЯЗЫВАЮЩИЕСЯ С EphA2, И МЕТОДЫ ИХ ИСПОЛЬЗОВАНИЯ | |
| JP2021184721A5 (enExample) | ||
| JP2019146572A5 (enExample) | ||
| JP2019107018A5 (enExample) | ||
| JP2022191301A5 (enExample) | ||
| JP2024059609A5 (enExample) | ||
| JP2014509835A5 (enExample) | ||
| JP2020019787A5 (enExample) | ||
| JP2013543498A5 (enExample) | ||
| JP2017522861A5 (enExample) | ||
| JP2020522280A5 (enExample) | ||
| JP2006507013A5 (enExample) | ||
| JP2010533498A5 (enExample) | ||
| JPWO2019224718A5 (enExample) | ||
| JP2017529838A5 (enExample) | ||
| JP2020522281A5 (enExample) | ||
| JP2020534830A5 (enExample) | ||
| JP2009297037A5 (enExample) | ||
| JP2010526028A5 (enExample) | ||
| NZ597067A (en) | Monoclonal antibodies expressed by ATCC PTA-4621 for the treatment of cancer | |
| JP2012525854A5 (enExample) | ||
| JP2011207882A5 (enExample) | ||
| JP2014524902A5 (enExample) | ||
| JPWO2019228266A5 (enExample) |